title: Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway.
abstract: Mesenchymal stem cells (MSCs) can suppress dendritic cells (DCs) maturation and function, mediated by soluble factors, such as indoleamine 2,3-dioxygenase (IDO), prostaglandin E(2) (PGE(2)), and nitric oxide (NO). Interleukin-10 (IL-10) is a common immunosuppressive cytokine, and the downstream signaling of the JAK-STAT pathway has been shown to be involved with DCs differentiation and maturation in the context of cancer. Whether IL-10 and/or the JAK-STAT pathway play a role in the inhibitory effect of MSCs on DCs maturation remains controversial. In our study, we cultured MSCs and DCs derived from rat bone marrow under different culturing conditions. Using Transwell plates, we detected by ELISA that the level of IL-10 significantly increased in the supernatants of MSC-DC co-cultures at 48 hours. The cell immunofluorescence assay suggested that the MSCs secreted more IL-10 than the DCs in the co-cultures. Adding exogenous IL-10 to the DCs monoculture or MSC-DC co-cultures stimulated IL-10 and led to a decrease in IL-12, and lower expression of the DCs surface markers CD80, CD86, OX62, MHC-II and CD11b/c. Supplementing the culture with an IL-10 neutralizing antibody (IL-10NA) showed precisely the opposite effect of adding IL-10. Moreover, we demonstrated that the JAK-STAT signaling pathway is involved in inhibiting DCs maturation. Both JAK1 and STAT3 expression and IL-10 secretion decreased markedly after adding a JAK inhibitor (AG490) to the co-culture plate. We propose that there is an IL-10 positive feedback loop, which may explain our observations of elevated IL-10 and enhanced JAK1 and STAT3 expression. Overall, we demonstrated that MSCs inhibit the maturation of DCs through the stimulation of IL-10 secretion, and by activating the JAK1 and STAT3 signaling pathway.
authors: Intensive Care Unit (ICU) Department, Second Affiliated Hospital of Harbin Medical University, Harbin, Province Heilongjiang, China.
authors: Wen-hua
authors: WH
authors: Liu
authors: Jing-jin
authors: JJ
authors: Liu
authors: Jian
authors: J
authors: Wu
authors: Lu-lu
authors: LL
authors: Zhang
authors: Fang
authors: F
authors: Liu
authors: Li
authors: L
authors: Yin
authors: Mao-mao
authors: MM
authors: Zhang
authors: Bo
authors: B
authors: Yu
mesh_terms: D000818:Animals; D002454:Cell Differentiation; D002478:Cells, Cultured; D018920:Coculture Techniques; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D016130:Immunophenotyping; D016753:Interleukin-10 / Q000378:metabolism* / Q000494:pharmacology; D018664:Interleukin-12 / Q000378:metabolism; D053613:Janus Kinase 1 / Q000378:metabolism*; D008070:Lipopolysaccharides / Q000276:immunology; D008297:Male; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000378:metabolism*; D010766:Phosphorylation; D051381:Rats; D050796:STAT3 Transcription Factor / Q000378:metabolism*; D015398:Signal Transduction; D020032:Tyrphostins / Q000494:pharmacology
chemical_list: D008070:Lipopolysaccharides; D050796:STAT3 Transcription Factor; D020032:Tyrphostins; C095512:alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide; D016753:Interleukin-10; D018664:Interleukin-12; D053613:Janus Kinase 1
references: Blood. 2009 Jun 25;113(26):6576-83
references: 19398717
references: Cell Immunol. 2011;267(1):30-8
references: 21145536
references: J Immunol. 2008 Sep 1;181(5):3277-84
references: 18713999
references: Annu Rev Immunol. 2003;21:685-711
references: 12615891
references: J Immunol. 2001 Apr 1;166(7):4312-8
references: 11254683
references: Biochem Pharmacol. 2010 Dec 15;80(12):2074-86
references: 20709027
references: Mol Med. 2011;17(7-8):697-708
references: 21365122
references: Immune Netw. 2010 Dec;10(6):219-29
references: 21286383
references: Lancet. 2004 May 1;363(9419):1439-41
references: 15121408
references: J Autoimmun. 2003 Jun;20(4):281-5
references: 12791313
references: Curr Cancer Drug Targets. 2007 Feb;7(1):71-7
references: 17305479
references: Annu Rev Immunol. 2001;19:683-765
references: 11244051
references: J Immunol. 1995 May 15;154(10):5071-9
references: 7730613
references: Immunol Invest. 2012;41(2):183-98
references: 21936678
references: Circ Res. 2008 Jul 18;103(2):125-7
references: 18635828
references: Stem Cells. 2008 Oct;26(10):2531-41
references: 18635870
references: J Immunol. 2011 Aug 15;187(4):1674-83
references: 21742974
references: Stem Cells. 2006 Mar;24(3):482-93
references: 16179426
references: J Immunol. 2008 Feb 1;180(3):1598-608
references: 18209056
references: Clin Vaccine Immunol. 2012 Aug;19(8):1207-17
references: 22695160
references: Blood. 2003 May 1;101(9):3722-9
references: 12506037
references: Cell Immunol. 2009;258(1):9-17
references: 19361784
references: Blood. 2008 Feb 1;111(3):1327-33
references: 17951526
references: Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2588-92
references: 8637918
references: J Immunol. 2007 Mar 1;178(5):2623-9
references: 17312100
references: Science. 1999 Apr 2;284(5411):143-7
references: 10102814
references: J Biomed Sci. 2003 Mar-Apr;10(2):228-41
references: 12595759
references: J Immunol. 2011 Sep 15;187(6):2875-84
references: 21844389
references: Stem Cells. 2007 Aug;25(8):2025-32
references: 17510220
references: Blood. 2009 Jan 1;113(1):46-57
references: 18832657
references: Blood. 2011 Jul 14;118(2):380-9
references: 21602525
references: Stem Cells Dev. 2007 Oct;16(5):719-31
references: 17999594
references: Mol Cells. 2011 Jun;31(6):497-507
references: 21533906
references: Blood. 2004 Jun 15;103(12):4619-21
references: 15001472
references: J Immunol. 2010 Nov 1;185(9):5102-10
references: 20889545